LAURA BOLEWARE: Open Payments
NPI 1437540325 · LAUREL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$612 in 30 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $612
Food & beverage: $612
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $89 |
| ABBVIE INC. | 4 | $74 |
| Janssen Biotech, Inc. | 4 | $70 |
| Lilly USA, LLC | 4 | $66 |
| ACADIA Pharmaceuticals Inc | 2 | $46 |
| ARGENX US, INC. | 2 | $38 |
| PFIZER INC. | 2 | $35 |
| SK Life Science, Inc. | 1 | $35 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $24 |
Products named: REXULTI, KISUNLA, NUPLAZID, VYVGART HYTRULO, NURTEC ODT, QULIPTA, INSPIRE, Symbravo.
Industry payments across MS — which companies pay providers there.
